migrane. Migraine
Conditions
Interventions
Intervention 1: The intervention group will receive 2 Mixodin capsules containing 300 mg curcumin, 7.5 mg gingerol, and 3.75 mg piperine daily for 8 weeks. Intervention 2: "Control group": They will r
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patients who agree to participate in the study Diagnosis of migraine by a neurologist based on criteria Age 20 to 60 years At least one year has passed since the diagnosis of migraine.
Exclusion criteria
Exclusion criteria: Cardiovascular diseases, blood pressure, diabetes, liver, kidney, thyroid, malignancies and other neurological disorders Suffering from tension headaches Changing the type of medicine used and its dosage during the last month Pregnancy and breastfeeding Taking supplements containing the active ingredients of Mixodin supplement including curcumin, gingerol and piperine following a special diet (vegetarian diets, Atkins diet and ketogenic diet) smoking Allergy to supplements Non-compliance with dietary recommendations and supplements (Use less than 80% of the prescribed supplement). Reaction and sensitivity to the prescribed supplement. Lack of referral in different stages of study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptoms of migraine (severity, frequency, duration of migraine attacks). Timepoint: At baseline and after 8 weeks. Method of measurement: Visual Analogue Scale (VAS) questionnaire and clinical examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Depression, stress, anxiety. Timepoint: At baseline and after 8 weeks. Method of measurement: DASS-21questionnaire.;Quality of Life in Migraine Patients. Timepoint: At baseline and after 8 weeks. Method of measurement: Migraine –Specific Quality of Life (MSQ) questionnaire.;Serum levels of High sensitive C-reactive protein (Hs-CRP). Timepoint: At baseline and after 8 weeks. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.;Serum Nitric Oxide. Timepoint: At baseline and after 8 weeks. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.;Total antioxidant capacity. Timepoint: At baseline and after 8 weeks. Method of measurement: biochemical kit of KiaZist Co.;Total oxidant status. Timepoint: At baseline and after 8 weeks. Method of measurement: biochemical kit of KiaZist Co.;Calcitonin gene-related peptide (CGRP). Timepoint: At baseline and after 8 weeks. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.;Malondialdehyde (MDA). Timepoint: At baseline and after 8 weeks. Method of measurement: biochemical kit of KiaZist Co.;Superoxide dismutase (SOD). Timepoint: At baseline and after 8 weeks. Method of measurement: biochemical kit of KiaZist Co. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Afsaneh Yegdaneh
Esfahan University of Medical Sciences
Outcome results
None listed